Torrent Pharmaceuticals Ltd · NSE:TORNTPHARM
Torrent Pharmaceuticals — Q1 FY2013 Earnings Presentation
21 slides from Torrent Pharmaceuticals's earnings presentation, 2012
Slide 1: Investor Presentation Q1 FY 2013
TORRENT PHARMACEUTICALS LTD Investor Presentation Q1 FY 2013
Slide 2: Caveat
Caveat This information may contain certain forward-looking statements/ details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expre
Slide 3: Contents
Contents 1. Performance Highlights 2. Financials 3. Business Segments – India – International 4. Facilities – Expansion Plan
Slide 4: Q1 FY13 Highlights
Q1 FY13 Highlights • Revenues at ` 7,669 Mn vs. ` 6,422 Mn. • Revenue growth of 19% on the back of robust growth from International operations • International sales boosted by US and Brazil operations. • PBT grows by 7% to ` 1404 Mn vs. ` 1313 Mn. • Adjusted for cut off sales in Brazil in correspond
Slide 5: Financials
Financials
Slide 6: Revenue Progression
Revenue Progression ` Mn P a rticu la rs Q1 Q1 1 1 -1 2 1 0 -1 1 12 - 13 11 - 12 In d ia 2778 2448 9091 8344 G w th % 13% 9% In te rn a tio n a l 4,212 3,160 14,783 11,219 G w th % 33% 32% B raz il 1355 1074 4769 3551 M ex ic o 48 28 158 61 G erm any (Heum ann) 783 834 3490 3016 US A 789 419 2162 11
Slide 7: P&L
P&L ` Mn Q1 Q1 P a r t ic u la r s 1 1 -1 2 1 0 -1 1 12 - 13 11 - 12 R evenues 7 ,6 6 9 6 ,4 2 2 2 6 ,9 5 9 2 1 ,9 7 8 C ogs 2 ,2 0 0 1 ,9 5 9 8 ,6 3 1 6 ,9 6 5 % R ev enues 29% 31% 32% 32% S G & A S pend 2 ,1 3 2 1 ,7 0 2 7 ,7 7 5 6 ,7 3 0 % R ev enues 28% 26% 29% 31% E m p lo y e e C o s t 1 ,5 3
Slide 8: Balance Sheet
Balance Sheet ` Mn Particulars 31-Mar-12 % 30-Jun-12 % ∆ EQUITY AND LIABILITIES Shareholders' Funds 11,938 65% 12,533 65% 595 Non-current liabilities 1,913 10% 1,945 10% 32 Loan Funds 4,602 25% 4,905 25% 304 Minority Interest 35 0% 46 0% 11 TOTAL 18,488 100% 19,430 100% 942 ASSETS Net Fixed Assets 9
Slide 9: Business Segments: India
Business Segments India
Slide 10: India: Highlights & Growth Drivers
India Highlights & Growth Drivers ` Mn Q1 Q1 India 11 - 12 10 - 11 12 - 13 11 - 12 Revenues 2778 2448 9091 8344 % Growth 13% 9% • Q1 FY 13 Highlights • IPM growth 11.8% Covered market growth 15.3%, Torrent growth 13.5% • Growth Gap mainly from Acute Therapy (CM: 13.9%, Torrent 11.9%, Internal 8%) •
Slide 11: Business Segments: International Operations
Business Segments International Operations
Slide 12: International: Highlights & Growth Drivers
Exports Highlights & Growth Drivers ` Mn Q1 Q1 International 11-12 10-11 12 - 13 11 - 12 Revenues 4,212 3,160 14,783 11,219 % Growth 33% 32% • Q1 FY 13 Highlights • Adjusting for cut off sales of Brazil in previous year, International revenue grows by 45% • US and Brazilian business major contributo
Slide 13: Brazil: Highlights & Growth Drivers
Brazil Highlights & Growth Drivers ` Mn Q1 Q1 Brazil 11-12 10-11 12 - 13 11 - 12 Revenues 1355 1074 4769 3551 % Growth 26% 34% • Q1 FY 13 Highlights • Reai growth of 28 % with volumes growing 17%, New Introductions 9%, Price growth 2%. • QTR (Mar- May) ~ Torrent growing at 12% vs. Covered Market gro
Slide 14: USA: Highlights & Growth Drivers
USA Highlights & Growth Drivers ` Mn Q1 Q1 USA 11-12 10-11 12 - 13 11 - 12 Revenues 789 419 2162 1143 % Growth 88% 89% • Q1 FY 13 Highlights • 38 ANDA's & 23 DMF’s approved till date (19 actively marketed, 8 under patent & 6 under cost improvement), 26 ANDAs (pending for approval) • 18 ANDA’s / 8 DM
Slide 15: Germany - Heumann: Highlights & Growth Drivers
Germany - Heumann Highlights & Growth Drivers ` Mn G e r m a ny Q1 Q1 1 1 -1 2 10 - 11 ( H e um a nn) 12 - 13 11 - 12 R e v e nue s 783 834 3490 3016 % G r o w th -6 % 16% • Q1 FY 13 Highlights • Euro sales de growth of 9% • Growth Drivers • Heumann successful in winning tenders • New Products going
Slide 16: Europe: Highlights & Growth Drivers
Europe (inc UK & Romania) Highlights & Growth Drivers ` Mn Europe Q1 Q1 11-12 10-11 (inc UK & Romania) 12 - 13 11 - 12 Revenues 532 383 1931 1476 %Growth 39% 31% • Q1 FY 13 Highlights - Dossier business revenue growth of 11%, Euro sales growth of 8% • Growth Drivers - New Product Pipeline – 30 produ
Slide 17: ROW: Highlights & Growth Drivers
ROW Highlights & Growth Drivers ` Mn Q1 Q1 ROW 11-12 10-11 12 - 13 11 - 12 Revenues 492 309 1571 1353 % Growth 59% 16% • Q1 FY13 Highlights • Adjusted for currency movements top line grew by 33% • Growth Drivers • Entry into semi-regulated markets like Thailand (Market Size of over USD 2 bio) • Incr
Slide 18: Mexico: Highlights & Growth Drivers
Mexico Highlights & Growth Drivers ` Mn Q1 Q1 Mexico 11-12 10-11 12 - 13 11 - 12 Revenues 48 28 158 61 % Growth 72% 158% • Q1 FY 13 Highlights • Growth in Mexican Peso 66% • Actively marketing 5 molecules in CNS • Field force of 35 people covering 70% of Mexican covered market. • Growth Drivers • Po
Slide 19: Facilities – Expansion Plan
Facilities – Expansion Plan
Slide 20: Facilities – Expansion Plan: Dahej SEZ
Facilities – Expansion Plan Dahej SEZ • Nature: Formulation & API Capacity Enhancement • Project Cost: ` 800 crores • Planned capacities: 50 TPA plus 11,000 million tablets / capsules p.a. • Timelines for completion: • Phase I: Project cost of ` 500 crores, commissioning in July 2014 • Phase II: Pro
Slide 21: Thank You
Thank You
Torrent Pharmaceuticals — Q1 FY2013 Earnings Presentation on 6ix